Search

Displaying results 6581 - 6590 of 9710 in total
  1. Drug

    Ancrod

    go.drugbank.com/drugs/DB05099
    ApprovedWithdrawn

    FDA granted a 'fast-track status' for investigation of ancrod use in patients suffering from acute ischemic stroke, a life threatening condition caused by the blockage of blood vessels supplying blood … Ancrod, marketed as Viprinex, is a defibrinogenating agent derived from Malayan pit viper venom. The defribrinogenation of blood results in an anticoagulant effect.

    Categories: Venombin A
  2. Drug

    Prinomastat

    go.drugbank.com/drugs/DB05100
    Investigational

    As a lipophilic agent, prinomastat crosses the blood-brain barrier. … Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity.

  3. Drug

    Rupintrivir

    go.drugbank.com/drugs/DB05102
    Experimental

    Rupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV) infections. … Rupintrivir was active against all 48 HRV serotypes tested in a cell protection assay in H1-HeLa cells. It is designed to combat colds caused by rhinovirus.

  4. Drug

    IR208

    go.drugbank.com/drugs/DB05106
    Investigational

    IR208 is currently undergoing Phase II studies in a 200-patient trial. … IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation.

  5. Drug

    16-Bromoepiandrosterone

    go.drugbank.com/drugs/DB05107
    Investigational

    16-Bromoepiandrosterone is an injectable formulation of a compound called alpha-epi-bromide. … It is a chemical relative of DHEA which was selected for development after it showed antiretroviral activity in laboratory tests.

  6. Drug

    Trabectedin

    go.drugbank.com/drugs/DB05109
    ApprovedInvestigational

    Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. … Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically.

    Categories: Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index
  7. Drug

    VIR201

    go.drugbank.com/drugs/DB05110
    Experimental

    is an experimental therapeutic vaccine currently in clinical trial. The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to AIDS.

  8. Drug

    EHC18

    go.drugbank.com/drugs/DB05114
    Experimental

    It is a broad spectrum of specific HCV proteins.

  9. Drug

    Thymectacin

    go.drugbank.com/drugs/DB05116
    Investigational

    Thymectacin, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine, is a novel small molecule anticancer agent. … Thymectacin was as efficacious as irinotecan, a drug recently approved for the treatment of 5-fluorouracil-resistant colon cancer.

  10. Drug

    IGN301

    go.drugbank.com/drugs/DB05117
    Experimental

    IGN301 is a cancer vaccine based on an anti-idiotypic antibody which provokes an immune response to Lewis Y. … Lewis Y is a carbohydrate molecule expressed on the surface of tumor cells of epithelial origin (e.g. lung, intestinal, breast, prostate or ovarian cancers).